垂体疾病新型冠状病毒感染临床应对指南

doi:10.16138/j.1673-6087.2023.01.006

摘要/Abstract

中图分类号:

R584
R511

中华医学会内分泌学分会. 垂体疾病新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 18-21.

Chinese Society of Endocrinology. Guidelines for clinical management of novel coronavirus infection in pituitary disease[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(01): 18-21.

参考文献 20

[1]	Yuen KCJ, Blevins LS Jr, Findling JW. Important ma-nagement considerations in patients with pituitary disorders during the time of the Covid-19 pandemic[J]. Endocr Pract, 2020, 26(8): 915-922. doi: 10.4158/EP-2020-0308 URL
[2]	Fleseriu M, Dekkers OM, Karavitaki N. Endocrinology in the time of COVID-19: management of pituitary tumours[J]. Eur J Endocrinol, 2020, 183(1): G17-G23. doi: 10.1530/EJE-20-0473 URL
[3]	Fleseriu M, Buchfelder M, Cetas JS, et al. Pituitary Society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective[J]. Pituitary, 2020, 23(4): 327-337. doi: 10.1007/s11102-020-01059-7 pmid: 32556793
[4]	Christ-Crain M, Hoorn EJ, Sherlock M, et al. Endocrinology in the time of COVID-19: management of diabetes insipidus and hyponatraemia[J]. Eur J Endocrinol, 2020, 183(1): G9-G15. doi: 10.1530/EJE-20-0338 URL
[5]	Christ-Crain M, Hoorn EJ, Sherlock M, et al. Endocrinology in the time of COVID-19-2021 updates: the management of diabetes insipidus and hyponatraemia[J]. Eur J Endocrinol, 2021, 185(4): G35-G42. doi: 10.1530/EJE-21-0596 pmid: 34292875
[6]	中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 751-760.
[7]	中国垂体腺瘤协作组. 中国肢端肥大症诊治共识(2021版)[J]. 中华医学杂志, 2021, 101(27): 2115-2126.
[8]	中国垂体腺瘤协作组. 中国库欣病诊治专家共识(2015)[J]. 中华医学杂志, 2016, 96(11): 835-840.
[9]	Isidori AM, Arnaldi G, Boscaro M, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency[J]. J Endocrinol Invest, 2020, 43(8): 1141-1147. doi: 10.1007/s40618-020-01266-w pmid: 32335855
[10]	Arlt W, Baldeweg SE, Pearce SHS, et al. Endocrinology in the time of COVID-19: management of adrenal insufficiency[J]. Eur J Endocrinol, 2020, 183(1): G25-G32. doi: 10.1530/EJE-20-0361 URL
[11]	Pal R, Joshi A, Bhadada SK, et al. Endocrine follow-up during post-acute COVID-19: practical recommendations based on available clinical evidence[J]. Endocr Pract, 2022, 28(4): 425-432. doi: 10.1016/j.eprac.2022.02.003 URL
[12]	中华医学会内分泌学分会肥胖学组. 肾上腺皮质功能减退症患者围手术期糖皮质激素管理专家共识[J]. 中华内分泌代谢杂志, 2022, 38(1): 1-6.
[13]	Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the endocrine system: a mini-review[J]. Endocrinology, 2022, 163(1):bqab203. doi: 10.1210/endocr/bqab203 URL
[14]	Tan T, Khoo B, Mills EG, et al. Association between high serum total cortisol concentrations and mortality from COVID-19[J]. Lancet Diabetes Endocrinol, 2020, 8(8): 659-660. doi: 10.1016/S2213-8587(20)30216-3 URL
[15]	Tan T, Khoo B, Mills EG, et al. Cortisol concentrations and mortality from COVID-19 - authors’ reply[J]. Lancet Diabetes Endocrinol, 2020, 8(10):809-810.
[16]	Pivonello R, Ferrigno R, Isidori AM, et al. COVID-19 and Cushing’s syndrome: recommendations for a special population with endogenous glucocorticoid excess[J]. Lancet Diabetes Endocrinol, 2020, 8(8): 654-656. doi: 10.1016/S2213-8587(20)30215-1 URL
[17]	Newell-Price J, Nieman LK, Reincke M, et al. Endocrinology in the time of COVID-19: management of Cushing’s syndrome[J]. Eur J Endocrinol, 2020, 183(1): G1-G7. doi: 10.1530/EJE-20-0352 URL
[18]	王卫庆, 单忠艳, 王广, 等. 新型冠状病毒肺炎疫情期间糖尿病基层管理专家建议[J]. 中华内分泌代谢杂志, 2020, 36(3): 185-190.
[19]	中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33(1): 1-10.
[20]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398.

垂体疾病新型冠状病毒感染临床应对指南

Guidelines for clinical management of novel coronavirus infection in pituitary disease

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 20

相关文章 13

编辑推荐

Metrics

本文评价

[1]	中华医学会内分泌学分会. 老年与儿童青少年糖尿病人群新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 10-12.
[2]	中华医学会内分泌学分会. 甲状腺功能异常新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 13-15.
[3]	中华医学会内分泌学分会. 肾上腺疾病新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 16-17.
[4]	中华医学会内分泌学分会. 骨质疏松症新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 22-24.
[5]	中华医学会内分泌学分会. 尿崩症患者新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 25-27.
[6]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下垂体疾病管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 130-132.
[7]	洪培伟, 丛雪, 徐严明. 2005至2020年中国西南地区肝豆状核变性住院费用影响因素分析[J]. 内科理论与实践, 2021, 16(05): 315-318.
[8]	金美玲, 墨玉清,. 关注重症哮喘合并症[J]. 内科理论与实践, 2018, 13(03): 133-137.
[9]	孙永昌,. 慢性阻塞性肺疾病合并症——关注心血管病诊治[J]. 内科理论与实践, 2012, 7(06): 405-407.
[10]	冯磊, 金立仁, 潘静薇, 魏盟,. 抗Jo-1抗体综合征合并心脏损害一例[J]. 诊断学理论与实践, 2009, 8(04): 456-457.
[11]	张豫文, 洪洁,. 糖耐量受损与冠心病的关系及其可能的影响因素[J]. 诊断学理论与实践, 2008, 7(03): 356-358.
[12]	李油山,任万武,王敏,王时美. 闭合性创伤性肠破裂180例临床分析[J]. 外科理论与实践, 2004, 9(03): 235-237.
[13]	李蔚萍,杨勇卫,黄磊,罗恩钊. 老年胃癌外科治疗85例分析[J]. 外科理论与实践, 2001, 6(04): 251-253.